HOME >> MEDICINE >> NEWS
Vaxfectin-formulated measles DNA vaccine elicits long-term protection in nonhuman primates

SEATTLEMay 31, 2007Vical Incorporated (Nasdaq:VICL) today announced that a measles DNA vaccine formulated with the company's Vaxfectin adjuvant elicited protective levels of neutralizing antibodies in juvenile (1 2 year old) nonhuman primates confirmed by complete protection following challenge more than one year after vaccination, and sterilizing immunity as evidenced by no clinical signs of disease and no detectable virus after challenge. In a separate study, the same vaccine elicited protective levels of neutralizing antibodies in infant (6 10 weeks old) nonhuman primates with no vaccine-related adverse events. The studies were conducted in collaboration with Diane E. Griffin, M.D., Ph.D., Alfred and Jill Sommer Professor and Chair of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, under a grant from the Bill and Melinda Gates Foundation.

"Sterilizing immunity is a rarely achieved ultimate goal in vaccination," said Vijay B. Samant, Vical's President and Chief Executive Officer. "The ability to provide such complete immunity with no adverse events offers proof of concept for Vaxfectin-formulated DNA vaccines. We look forward to continued development of the measles vaccine program by our collaborators at Johns Hopkins."

"We have tested a number of measles DNA vaccines, and the data relating to Vical's Vaxfectin-formulated DNA vaccine showed marked differences both in terms of disease resistance after exposure and antibody levels over the other vaccines, without significant side effects," said Dr. Griffin. "These data are exciting because of the potential of providing safety and efficacy suitable for infants and young children in the developing world, and continued development could result in a major impact on global measles disease and death rates."

The study in juvenile rhesus macaques tested the protective efficacy of a bivalent DNA vaccine encoding measles hemagglutinin and fusion glycop
'"/>

Contact: Kim Richards
krichards@pnlifesciences.com
Porter Novelli, Life Sciences
31-May-2007


Page: 1 2

Related medicine news :

1. Vulnerability to measles among nursery school children risen sharply
2. New study shows measles immunization may prevent fatal brain infection
3. Traditional Chinese exercises may increase efficacy of flu vaccine
4. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
5. Study reveals gaps in vaccine financing for underinsured children
6. Trials underway for essential new TB vaccine
7. Hib vaccine: A critical ally in Asias effort to reduce child deaths
8. Progress toward an antitumor vaccine
9. Chemotherapy may enhance the effectiveness of brain tumor vaccines
10. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
11. International studies show high efficacy for HPV vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/24/2017)... ... 24, 2017 , ... In “Sky and I”, a young boy was walking home and feeling down about himself. ... him otherwise. The new friend says he can do whatever he wants to do if ... enough just the way he is. God created him with special talents and gifts. We ...
(Date:9/24/2017)... (PRWEB) , ... September 24, 2017 , ... “The Gospel Truth Of The Bible: The ... “The Gospel Truth Of The Bible: The Other Sheep” is the creation of published author, ... born in the West Indies. He has been a member of the Seventh-day Adventist ...
(Date:9/23/2017)... ... September 23, 2017 , ... Silicon Valley Hair Institute, the leading ... new blog post focused on the ARTAS® hair transplant system and the younger demographic. ... the latest, most technologically sophisticated methods of hair restoration. , “It can be emotionally ...
(Date:9/22/2017)... ... ... MEDIA OPPORTUNITY: , Save Our Hospital - Albert Lea will host media ... against Mayo Clinic. Specifically, media can talk to steering committee members and patients regarding ... the Albert Lea hospital. , The rally aims to protect the most vulnerable and ...
(Date:9/22/2017)... PA (PRWEB) , ... September 22, 2017 , ... ... soon as possible, and they often saves lives. However, if one isn’t accessible ... to widen the availability of defibrillation, I came up with this idea," said ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... -- NeuroRx, a clinical stage biopharma company developing the first ... been granted Fast Track status by the US Food and ... followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly ... therapy targeting patients who are admitted to Emergency Departments with ... ...
(Date:9/5/2017)... another milestone in their continued growth and success of the company.  Xyntek has ... engagements regionally.  ... at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office will support the ... In addition to Xyntek,s headquarters ...
(Date:9/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... its meeting with the U.S. Food and Drug Administration ... At the meeting, ... for submission of ORMD-0801, would be a Biologics License ...
Breaking Medicine Technology:
Cached News: